Fosamprenavir CalciumThird Party Manufacturing in India

Fosamprenavir Calcium is a phosphate ester prodrug of amprenavir that is rapidly and extensively hydrolyzed to amprenavir in the gastrointestinal tract epithelium before reaching the systemic circulation. Amprenavir, the active moiety, is a potent HIV-1 protease inhibitor that competitively binds to the active site of the HIV-1 protease enzyme. This enzyme is essential for the proteolytic cleavage of viral Gag and Gag-Pol polyproteins into individual functional proteins required for the assembly and maturation of infectious viral particles. By inhibiting HIV-1 protease, fosamprenavir prevents the maturation of newly formed viral particles, resulting in the production of immature, non-infectious virions. This effectively blocks viral replication and reduces plasma HIV-1 RNA levels. Fosamprenavir is typically co-administered with low-dose ritonavir, a potent CYP3A4 inhibitor, which boosts amprenavir plasma concentrations by inhibiting its metabolism, thereby reducing the required dose and improving the pharmacokinetic profile.

Therapeutic Uses

Fosamprenavir Calcium is prescribed for the treatment of:

• HIV-1 Infection: Used in combination with other antiretroviral agents such as ritonavir, abacavir, lamivudine, or tenofovir for the treatment of HIV-1 infection in adults and pediatric patients aged 2 years and older.
• Initial HIV Therapy: Demonstrated non-inferior efficacy compared to lopinavir/ritonavir in treatment-naive patients when combined with abacavir/lamivudine.
• Treatment-Experienced Patients: Effective in patients who have received prior antiretroviral therapy, including those with resistance to other protease inhibitors.

Why Manufacturers Choose Fosamprenavir Calcium

Fosamprenavir offers a significant advantage over its predecessor amprenavir through reduced pill burden and improved solubility, making it a preferred choice in antiretroviral therapy regimens. As a prodrug, it provides better oral bioavailability and can be taken with or without food. The molecule is primarily relevant for WHO-GMP certified manufacturers serving export markets, particularly to countries with government-funded antiretroviral programs. Its high potency (700mg tablet) means lower raw material requirements per dose compared to many other antiretrovirals. While the addressable market is more specialized than general therapeutic categories, the consistent demand from HIV treatment programs and the molecule's inclusion in international treatment guidelines make it a valuable addition to an antiretroviral manufacturing portfolio.